Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

34.70 +0.21 (+0.61%)

Streaming Delayed Price Updated: 11:04 AM EDT, Sep 3, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	202,926
Open	34.49
Bid (Size)	34.70 (100)
Ask (Size)	34.79 (200)
Prev. Close	34.49
Today's Range	34.11 - 35.31
52wk Range	9.145 - 41.14
Shares Outstanding	67,176,067
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%? ↗

September 01, 2026

Amylyx looks promising, but a pullback would improve the opportunity.

Via The Motley Fool

Should Eli Lilly Investors Be Worried About a Threat From Amylyx? ↗

August 30, 2026

Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate.

Via The Motley Fool

Performance

YTD	+203.9%	+203.9%
1 Month	+72.0%	+72.0%
3 Month	+162.9%	+162.9%
6 Month	+130.6%	+130.6%
1 Year	+247.7%	+247.7%

More News

Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week ↗

August 21, 2026

Via The Motley Fool

Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock

August 19, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals (NASDAQ:AMLX) Misses on Q2 Bottom Line as LUCIDITY Readout Looms ↗

August 06, 2026

Via Chartmill

Why Amylyx Pharmaceuticals Stock Skyrocketed Today ↗

August 18, 2026

Via The Motley Fool

Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock

August 18, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

August 18, 2026

Via Benzinga

Amylyx Phase III Avexitide Trial Cuts Severe Hypoglycemic Events 55% ↗

August 18, 2026

Via MarketBeat

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

August 18, 2026

Via Benzinga

Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

August 18, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026

August 17, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx (AMLX) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

Via The Motley Fool

Amylyx Pharmaceuticals Q2 Earnings Call Highlights ↗

August 06, 2026

Via MarketBeat

Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results

August 06, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

August 03, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026

June 23, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shape ↗

June 10, 2026

Via MarketBeat

Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026

June 08, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

What to Know About This Fund's $10 Million Bet on Gold Miners ↗

May 24, 2026

Via The Motley Fool

Amylyx Stock: Why the Full Pipeline Story Matters ↗

May 24, 2026

Via MarketBeat

Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares ↗

May 19, 2026

Via The Motley Fool

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors ↗

May 19, 2026

Via The Motley Fool

Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation

May 15, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Eyes Phase 3 AVEXITIDE Readout as 2027 Launch Comes Into Focus ↗

May 14, 2026

Via MarketBeat

Frequently Asked Questions

Is Amylyx Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Amylyx Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Amylyx Pharmaceuticals, Inc. - Common Stock trade on?

Amylyx Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Amylyx Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Amylyx Pharmaceuticals, Inc. - Common Stock is AMLX on the Nasdaq Stock Market

What is the current price of Amylyx Pharmaceuticals, Inc. - Common Stock?

The current price of Amylyx Pharmaceuticals, Inc. - Common Stock is 34.70

When was Amylyx Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Amylyx Pharmaceuticals, Inc. - Common Stock was at 09/03/26 11:04 AM ET

What is the market capitalization of Amylyx Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Amylyx Pharmaceuticals, Inc. - Common Stock is 2.33B

How many shares of Amylyx Pharmaceuticals, Inc. - Common Stock are outstanding?

Amylyx Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.